Government & Policy
This week's top stories include Under Armour throwing all its weight behind MapMyFitness, HHS unveiling its 2020-2025 Federal Health IT Strategic Plan, and CMS approving a Georgia waiver for a non-ACA marketplace.
This week's top stories include malicious actors looking to infect health systems on a large scale, and provider groups pushing back against Trump's claims that doctors are inflating COVID-19 numbers.
Government awards startup $481M for coronavirus testing; public hospitals compounding COVID-19 budget risks
This week's top stories include Cue Health delivering 100,000 COVID-19 tests per day by March, and hospital associations calling CMS' threat to withhold Medicare and Medicaid participation for non-compliant data reporting "reckless."
This week's top stories include hospitals needing to report flu information in addition to COVID-19 data, while Americans want mental healthcare via telehealth but worry about data security.
The experience of the pandemic is strengthening the Skolkovo region as regulation changes are accelerating innovation, says Natalia Polushkina, vice president and CEO at Biomedical Technologies Cluster of the Skolkovo Foundation.
Providers and citizens in Sweden have an open mindset, enabling rapid digital transformation to take place effectively during the pandemic, says Daniel Forslund, chairman of the Innovation and Development Committee in Region Stockholm.
One goal of Kuwait's 2035 vision is to strengthen investment in high-quality healthcare, which has already led to increased efficiency, use of innovative technology and a changing culture.
This week's top stories include a look at what the passing of Supreme Court Justice Ginsburg could mean for the Affordable Care Act, femtech companies bemoaning advertising difficulties on social media and the emergence of social informatics.
Wales is prioritizing tools that are popular with patients, says Ifan Evans, director of technology, digital & transformation for the Welsh Government Health and Social Services.
Dr. Amy Abernethy, principal deputy commissioner at the U.S. FDA, discusses the need for regulatory "agility" during the COVID-19 pandemic.